Key takeaways
Wegovy (semaglutide) was initially available only as an injectable GLP-1 medication, but is now available as oral tablets.
Before Wegovy pills were approved, Rybelsus was the only oral semaglutide product on the market.
Wegovy pills and pens are similar in effectiveness and cost but have different FDA approvals.
Wegovy (semaglutide) is a prescription GLP-1 medication initially approved by the Food and Drug Administration (FDA) for chronic weight management when combined with diet and exercise. Since its initial approval for weight loss, it’s also been approved to reduce cardiovascular risk and treat a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). For those who would rather avoid needles or cannot use injectable medications, oral alternatives might be more appealing. In this article, learn more about oral forms of semaglutide, how they compare to injectable Wegovy, and what alternatives may be available.
RELATED: How much does Wegovy cost?
Does Wegovy come in pill form?
Yes, an oral form of Wegovy was FDA approved in December, 2025. Another oral form of semaglutide, Rybelsus, has been available since 2019, but it is only FDA approved for Type 2 diabetes.
There may be online telehealth services that offer compounded oral semaglutide in the form of a liquid drop, tablet, or lozenge. It’s important to know that compounded medications aren’t approved by the FDA, and the FDA has warned against the use of compounded GLP-1s because of the potential risks regarding safety, effectiveness, and quality.
Jennifer Brown, MD, board-certified obesity medicine specialist at MyObesityTeam, explains why patients should be wary of compounded oral semaglutide offered online: “I generally advise patients to steer clear of compounded oral semaglutide. While it may be less expensive, it’s impossible to tell what components at what amounts are actually in the compounded version without an independent lab evaluation,” she says. Wegovy is found to be more effective for weight loss and has less incidence of side effects when the dose is increased over time.
Compare Wegovy pill vs. injection |
||
|---|---|---|
| Differences | Wegovy pill | Wegovy pen |
| Dosage | 1.5 mg, 4 mg, 9 mg, 25 mg | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg |
| Indication |
|
|
| SingleCare’s lowest price | $1,086 for 30, 1.5 mg tablets at Kroger or Harris Teeter | $1,209 for 4, 2.4 mg pens at Publix |
Prescription drug prices often change. These are the most accurate medication prices at the time of publishing in ZIP code 23666 as of March 25, 2026.
Wegovy pill vs. injection dosage
Wegovy pills are available in the following doses:
- 1.5 mg for days 1–30
- 4 mg for days 31–60
- 9 mg for days 61–90
- 25 mg for days 91 and onward
Wegovy injections are available in the following doses:
- 0.25 mg for weeks 1–4
- 0.5 mg for weeks 5–8
- 1 mg for weeks 9–12
- 1.7 mg for weeks 13–16 or longer
The maximum dose of Wegovy is 2.4 mg each week from week 17 onward. Your healthcare provider will determine the right Wegovy dose for you. Once you achieve your desired weight, your healthcare provider may recommend decreasing or spacing out your doses.
Wegovy pill vs. injection effectiveness
In its clinical trials, Wegovy tablets and pens produced similar weight loss results, although results were slightly higher among patients who use the pens. Those who used the injectable pens lost an average of 15% of their initial body weight after 68 weeks, while those who used the oral tablets lost about 14% of their body weight after 64 weeks.
The reason for the slightly higher amount of weight loss with Wegovy pens is that injectable medications are more reliably absorbed through the bloodstream. In contrast, oral tablets are absorbed through the digestive system, where factors such as food and metabolism affect how quickly they’re absorbed. It may also be easier to remember to take a once-weekly injection versus a daily oral medication.
Are there any other oral GLP-1s for weight loss?
As of this writing, there aren’t any other approved oral GLP-1 weight loss drugs, but there are ongoing studies that are promising.
An oral GLP-1 called orforglipron, being developed by drugmaker Lilly, has shown some promising results for weight loss. Compared to a placebo treatment, the daily orforglipron reduced body weight by an average of 12% after 72 weeks of treatment. Clinical trials on this drug started in 2023, and more results are expected in 2025.
Another GLP-1 being studied for Type 2 diabetes is called danuglipron. Though not the main aim for these clinical studies, one trial published in 2023 showed that after 16 weeks of treatment, the average weight loss was 4–9 lbs on danuglipron. In April 2025, the drug company Pfizer discontinued development of the medication for weight loss.
Though Rybelsus is the first oral GLP-1 drug approved for Type 2 diabetes only, it also has some research behind its use in people managing their weight. A clinical study published in 2023 found that study subjects lost on average 15% of their body weight compared to placebo while on 50 mg, the highest dose of oral semaglutide, for 68 weeks.
Save on weight loss medication
Wegovy alternatives without needles
There are other prescription, oral alternatives to Wegovy, such as:
- Contrave (naltrexone and bupropion)
- Qsymia (phentermine and topiramate extended release)
- Adipex-P (phentermine)
- Xenical (orlistat)
- Tenuate (diethylpropion)
Other oral medications for Type 2 diabetes can help someone manage their weight as well. “For patients who prefer pills, I lean toward Rybelsus or metformin. Jardiance (empagliflozin) is also a great option for diabetic patients,” she says.
Lifestyle changes should not be overlooked as effective, non-injectable alternatives. Most medical guidelines emphasize that a reduced-calorie diet and increased physical activity are the foundations of obesity treatment. Dr. Aravamudhan provides examples of some lifestyle changes that can be helpful for people managing chronic high weight:
- A diet high in protein with lean meats, lentils, and legumes, with lots of fruits, vegetables, whole grains, nuts, and plain yogurt
- Adequate hydration with plain water, avoiding drinks with added sugars and sweeteners
- Regular daily aerobic exercises, resistance training, and stretching
- Getting enough sleep, about seven to eight hours per night
- Learning to manage stress with proper physical and psychological tools
- Practicing mindful eating with portion control to reduce emotional eating
Other than your primary care provider or endocrinologist, it may help to manage chronic conditions like obesity with guidance from other healthcare professionals, according to Dr. Aravamudhan. Nutritionists, mental health professionals, personal trainers, or exercise therapists can help achieve desired outcomes and help minimize side effects and injuries.
Ultimately, the right choices for you will depend on many factors, including your medical history, lifestyle, and healthcare team. Always talk with your healthcare provider about which treatment approach is best for you, whether it’s oral prescription medication, lifestyle changes, or a combination of them.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2025)
- Label: WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet, DailyMed (2026)
- Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity, Lilly (2025)
- Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes, a randomized clinical trial, JAMA Network Open (2023)
- Pfizer provides update on oral GLP-1 receptor agonist danuglipron, Pfizer (2025)
- Oral semaglutide, Clinical Diabetes (2020)
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2023)
- A review of current guidelines for the treatment of obesity, American Journal of Managed Care (2022)